Search research articles
Contact Us
Filters
Showing results (131-140 of 147) with videos related to
Page
of 15
Sort By:
Journal for Immunotherapy of Cancer
|
December 22, 2021
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Yunpeng Yang, Ting Zhou, Xiaozhong Chen, et al.
BMJ (Clinical Research Ed.)
|
March 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
Zhi Peng, Yanqiao Zhang, Huiting Xu, et al.
Medcomm
|
April 23, 2026
Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study
Ting Zhou, Haishuang Sun, Gang Chen, et al.
Pharmaceutical Biology
|
May 21, 2024
Guidelines for the clinical application of the <i>Xihuang</i> pill for the prevention and treatment of breast hyperplasia diseases
Hongmei Tang, Qin Lu, Shiyin Feng, et al.
The Lancet. Oncology
|
May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, et al.
Cancer Cell
|
May 19, 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Yunpeng Yang, Jianji Pan, Hui Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li, Qitao Yu, Qing Bu, et al.
Frontiers in Oncology
|
May 9, 2022
Immortal Time Bias-Corrected Effectiveness of Traditional Chinese Medicine in Non-Small Cell Lung Cancer (C-EVID): A Prospective Cohort Study
Xing Zhang, Qiujun Guo, Conghuang Li, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
Journal of the National Cancer Center
|
July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)
Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 147) with videos related to
Sort By:
Page
of 15
Journal for Immunotherapy of Cancer
|
December 22, 2021
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Yunpeng Yang, Ting Zhou, Xiaozhong Chen, et al.
BMJ (Clinical Research Ed.)
|
March 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
Zhi Peng, Yanqiao Zhang, Huiting Xu, et al.
Medcomm
|
April 23, 2026
Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study
Ting Zhou, Haishuang Sun, Gang Chen, et al.
Pharmaceutical Biology
|
May 21, 2024
Guidelines for the clinical application of the <i>Xihuang</i> pill for the prevention and treatment of breast hyperplasia diseases
Hongmei Tang, Qin Lu, Shiyin Feng, et al.
The Lancet. Oncology
|
May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, et al.
Cancer Cell
|
May 19, 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Yunpeng Yang, Jianji Pan, Hui Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li, Qitao Yu, Qing Bu, et al.
Frontiers in Oncology
|
May 9, 2022
Immortal Time Bias-Corrected Effectiveness of Traditional Chinese Medicine in Non-Small Cell Lung Cancer (C-EVID): A Prospective Cohort Study
Xing Zhang, Qiujun Guo, Conghuang Li, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
Journal of the National Cancer Center
|
July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)
Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.
Page
of 15